...(technical difficulty) to 2020, 2021, 2022. So '23 was a stronger year of utilization. As we stepped into '24 we assume those strong levels of utilization would continue through the entire year. So our pricing anticipated that our guidance anticipated that and our projections did as well. So we are pleased with our first quarter results coming in better than expectations in Cigna Healthcare, where the MCR was better than we had projected and also the income was ahead of expectations which, again, we come back to the firm pricing that we've had in the market 2024, reflecting that utilization is consistent with what we experienced in the first quarter. So far, the second quarter is largely in line with what we had expected coming out of the first quarter, which again is persistently high utilization levels relative to what we had in '23. In the first quarter, we had strong levels of inpatient utilization, a little bit of decelerating outpatient and surgery utilization, but still at high levels...
